PATENT CLAIM ANALYSIS

Application Number: 15869630
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["435", "325000"]

Abstract:
The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

Claim (Index 41):
The method of  claim 1 , wherein the composition comprising coenzyme Q10 is administered by continuous intravenous infusion for about 96 hours, and wherein the composition is administered sequentially at a first rate, a second rate, and a third rate wherein:\n (a) the first rate is a highest rate administered during the first hour of the continuous intravenous infusion; (b) the second rate is a lowest rate administered during hours 2 to 48 of the continuous intravenous infusion; and (c) the third rate is an intermediate rate between the first rate and the second rate and is administered during hours 49 to 96 of the continuous intravenous infusion.

Metadata:
- Claim Count in Document: 188.0
- Percentile: 86.0
- Lexical Diversity: 1.6
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14477828', '11434154', '15376243', '14867554', '12467214']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5609636384322725
- 35 USC 102 Novelty (BERT): 0.6814305804432769
- Combined Prediction Score: 0.5730103326333729
- Mean Citation Score: 365.43693
- Max Citation Score: 703.2847
- Similarity Product: 666.0474345922112

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test